Lifeline Biotechnologies Financials
| LLBO Stock | USD 0.0001 0.0003 75.00% |
Lifeline |
Lifeline Biotechnologies Stock Summary
Lifeline Biotechnologies competes with Cellink AB, Bone Biologics, BICO Group, Aurora Spine, and Tenon Medical. Lifeline Biotechnologies, Inc. operates as a medical technology company in the United States. Lifeline Biotechnologies, Inc. is headquartered in Reno, Nevada. Lifeline Biotech operates under Medical Devices classification in the United States and is traded on OTC Exchange.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US53219E8084 |
| Business Address | 1325 Airmotive Way, |
| Sector | Healthcare |
| Industry | Medical Devices |
| Benchmark | Dow Jones Industrial |
| Website | www.lbti.co |
| Phone | 775 852 3222 |
| Currency | USD - US Dollar |
Lifeline Biotechnologies Key Financial Ratios
Lifeline Biotechnologies' financial ratios allow both analysts and investors to convert raw data from Lifeline Biotechnologies' financial statements into concise, actionable information that can be used to evaluate the performance of Lifeline Biotechnologies over time and compare it to other companies across industries.| Beta | -1.86 | |||
| Z Score | 14.4 |
Lifeline Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lifeline Biotechnologies's current stock value. Our valuation model uses many indicators to compare Lifeline Biotechnologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lifeline Biotechnologies competition to find correlations between indicators driving Lifeline Biotechnologies's intrinsic value. More Info.Lifeline Biotechnologies is rated fifth overall in current valuation category among its peers. It is currently regarded as number one stock in net income category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Lifeline Biotechnologies by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Lifeline Biotechnologies' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Lifeline Biotechnologies Systematic Risk
Lifeline Biotechnologies' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Lifeline Biotechnologies volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Lifeline Biotechnologies correlated with the market. If Beta is less than 0 Lifeline Biotechnologies generally moves in the opposite direction as compared to the market. If Lifeline Biotechnologies Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Lifeline Biotechnologies is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Lifeline Biotechnologies is generally in the same direction as the market. If Beta > 1 Lifeline Biotechnologies moves generally in the same direction as, but more than the movement of the benchmark.
Lifeline Biotechnologies December 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Lifeline Biotechnologies help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Lifeline Biotechnologies. We use our internally-developed statistical techniques to arrive at the intrinsic value of Lifeline Biotechnologies based on widely used predictive technical indicators. In general, we focus on analyzing Lifeline Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Lifeline Biotechnologies's daily price indicators and compare them against related drivers.
| Downside Deviation | 63.22 | |||
| Information Ratio | 0.1604 | |||
| Maximum Drawdown | 375.0 | |||
| Value At Risk | (66.67) | |||
| Potential Upside | 100.0 |
Other Information on Investing in Lifeline Pink Sheet
Lifeline Biotechnologies financial ratios help investors to determine whether Lifeline Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Lifeline with respect to the benefits of owning Lifeline Biotechnologies security.